迪哲医药：预计2025年净利润亏损7.7亿元左右

Core Viewpoint - Dize Pharmaceutical (688192.SH) forecasts a net loss of approximately 770 million yuan for the fiscal year 2025, which represents a reduction in losses of about 75.96 million yuan compared to the same period last year [1] Group 1 - The company expects its sales revenue to reach around 800 million yuan, marking a year-on-year increase of 122.28% [1] - Two approved products, Shuwozhe and Gaoruizhe, have been included in the national medical insurance drug list, contributing to the sales growth [1]